[1]
|
[1]Galle, P.C. (1989) Clinical Presentation and Diagnosis of Endometriosis. Obstetrics and Gynecology Clinics of North America, 16, 29-42.
|
[2]
|
Simmons, S., Hummelshog, L. and D’Hooge, T. (2007) Endometriosis: Cost Estimates and Methodological Perspective. Human Reproduction Update, 13, 395-344. http://dx.doi.org/10.1093/humupd/dmm010
|
[3]
|
Stratton, P. and Berksley, K.J. (2011) Chronic Pelvic Pain and Endometriosis: Translational Evidence of the Relationship and Implications. Human Reproduction Update, 17, 327-348. http://dx.doi.org/10.1093/humupd/dmq050
|
[4]
|
Garrido, N., Navarro, J., García-Velasco, J., Remohí, J., Pellicer, A. and Simón, C. (2002) The Endometrium versus Embryonic Quality in Endometriosis-Related Infertility. Human Reproduction Update, 8, 95-100.
http://dx.doi.org/10.1093/humupd/8.1.95
|
[5]
|
Bulleti, C., Coccia, M.E., Baltistani, S. and Borini, A. (2010) Endometriosis and Infertility. Journal of Assisted Reproduction and Genetics, 27, 441-447.
|
[6]
|
Gilmour, J.A., Huntington, A. and Wilson, H.V. (2008) The Impact of Endometriosis on Work and Social Participation. International Journal of Nursing Practice, 14, 443-448. http://dx.doi.org/10.1111/j.1440-172X.2008.00718.x
|
[7]
|
Donnez, J., Nisolle, M., Casanas-Roux, F., Bassil, S. and Anaf, V. (1995) Rectovaginal Septum, Endometriosis or Adenomyosis: Laparoscopic Management in a Series of 231 Patients. Human Reproduction, 10, 630-635.
|
[8]
|
Nisolle, M. and Donnez, J. (1997) Peritoneal Endometriosis, Ovarian Endometriosis, and Adenomyotic Nodules of the Rectovaginal Septum Are Three Different Entities. Fertility and Sterility, 68, 585-596.
http://dx.doi.org/10.1016/S0015-0282(97)00191-X
|
[9]
|
Tokushige, N., Markham, R., Russell, P. and Fraser, I.S. (2006) Nerve Fibres in Peritoneal Endometriosis. Human Reproduction, 21, 3001-3007. http://dx.doi.org/10.1093/humrep/del260
|
[10]
|
McKinnon, B., Bersinger, N.A., Wotzkow, C. and Mueller, M.D. (2012) Endometriosis-Associated Nerve Fibers, Peritoneal Fluid Cytokine Concentrations, and Pain in Endometriotic Lesions from Different Locations. Fertility and Sterility, 97, 373-380. http://dx.doi.org/10.1016/j.fertnstert.2011.11.011
|
[11]
|
Johnson, N.P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium (2013) Consensus on Current Management of Endometriosis. Human Reproduction, 28, 1552-1568.
http://dx.doi.org/10.1093/humrep/det050
|
[12]
|
Streuli, I., de Ziegler, D., Santulli, P., et al. (2013) An Update on the Pharmacological Management of Endometriosis. Expert Opinion on Pharmacotherapy, 14, 291-305. http://dx.doi.org/10.1517/14656566.2013.767334
|
[13]
|
Allen, C., Hopewell, S., Prentice, A. and Gregory, D. (2009) Nonsteroidal Antiinflammatory Drugs for Pain in Women with Endometriosis. Cochrane Database of Systematic Reviews, 2, CD004753.
|
[14]
|
Sampson, J.A. (1927) Peritoneal Endometriosis Due to the Menstrual Dissemination of Endometrial Tissue into the Peritoneal Cavity. American Journal of Obstetrics & Gynecology, 14, 442-469.
http://dx.doi.org/10.1016/S0002-9378(15)30003-X
|
[15]
|
Bulun, S.E. (2009) Endometriosis. The New England Journal of Medicine, 360, 268-279.
http://dx.doi.org/10.1056/NEJMra0804690
|
[16]
|
Santulli, P., Marcellin, L., Noël, J.C., Borghese, B., Fayt, I., Vaiman, D., Chapron, C. and Méhats, C. (2012) Sphingosine Pathway Deregulation in Endometriotic Tissues. Fertility and Sterility, 97, 904-911.
http://dx.doi.org/10.1016/j.fertnstert.2011.12.051
|
[17]
|
González-Ramos, R., Van Langendonckt, A., Defrère, S., Lousse, J.C., Colette, S., Devoto, L. and Donnez, J. (2010) Involvement of the Nuclear Factor-κB Pathway in the Pathogenesis of Endometriosis. Fertility and Sterility, 94, 1985- 1994. http://dx.doi.org/10.1016/j.fertnstert.2010.01.013
|
[18]
|
Yagyu, T., Kobayashi, H., Matsuzaki, H., et al. (2005) Thalidomide Inhibits Tumor Necrosis Factor-α-Induced Interleukin-8 Expression in Endometriotic Stromal Cells, Possibly through Suppression of Nuclear Factor-κB Activation. The Journal of Clinical Endocrinology & Metabolism, 90, 3017-3021. http://dx.doi.org/10.1210/jc.2004-1946
|
[19]
|
Huber, A.V., Saleh, L., Prast, J., Haslinger, P. and Knöfler, M. (2007) Human Chorionic Gonadotrophin Attenuates NF-κB Activation and Cytokine Expression of Endometriotic Stromal Cells. Molecular Human Reproduction, 13, 595- 604. http://dx.doi.org/10.1093/molehr/gam032
|
[20]
|
Grund, E.M., Kagan, D., Tran, C.A., Zeitvogel, A., Starzinski-Powitz, A., Nataraja, S. and Palmer, S.S. (2008) Tumor Necrosis Factor-α Regulates Inflammatory and Mesenchymal Responses via Mitogen-Activated Protein Kinase Kinase, p38, and Nuclear Factor κB in Human Endometriotic Epithelial Cells. Molecular Pharmacology, 73, 1393-1404.
http://dx.doi.org/10.1124/mol.107.042176
|
[21]
|
Zhang, J.-J., Xu, Z.-M., Dai, H.-Y., Ji, X.-Q., Duan, Y.-Y., Zhang, C.-M. and Qin, D.-Y. (2010) Application of the Nuclear Factor-κB Inhibitor Pyrrolidine Dithiocarbamate for the Treatment of Endometriosis: An in Vitro Study. Fertility and Sterility, 94, 2942-2944. http://dx.doi.org/10.1016/j.fertnstert.2010.05.009
|
[22]
|
Soares, S.R., Martínez-Varea, A., Hidalgo-Mora, J.J. and Pellicer, A. (2012) Pharmacologic Therapies in Endometriosis: A Systematic Review. Fertility and Sterility, 98, 529-555. http://dx.doi.org/10.1016/j.fertnstert.2012.07.1120
|
[23]
|
Barrier, B.F. (2010) Immunology of Endometriosis. Clinical Obstetrics & Gynecology, 53, 397-402.
http://dx.doi.org/10.1097/GRF.0b013e3181db7c33
|
[24]
|
Mathur, S.P. (2000) Autoimmunity in Endometriosis: Relevance to Infertility. American Journal of Reproductive Immunology, 44, 89-95. http://dx.doi.org/10.1111/j.8755-8920.2000.440204.x
|
[25]
|
De Ziegler, D., Borghese, B. and Chapron, C. (2010) Endometriosis and Infertility: Pathophysiology and Management. The Lancet, 376, 730-738. http://dx.doi.org/10.1016/S0140-6736(10)60490-4
|
[26]
|
Slabe, N., Meden-Vrtovec, H., Verdenik, I., Kosir-Pogacnik, R. and Ihan, A. (2013) Cytotoxic T-Cells in Peripheral Blood in Women with Endometriosis. Geburtshilfe Frauenheilkd, 73, 1042-1048.
http://dx.doi.org/10.1055/s-0033-1350702
|
[27]
|
May, K.E., Conduit-Hulbert, S.A., Villar, J., et al. (2010) Peripheral Biomarkers of Endometriosis: A Systematic Review. Human Reproduction Update, 16, 651-674. http://dx.doi.org/10.1093/humupd/dmq009
|
[28]
|
Khoufache, K., Michaud, N., Harir, N., Kibangou Bondza, P. and Akoum, A. (2012) Anomalies in the Inflammatory Response in Endometriosis and Possible Consequences: A Review. Minerva Endocrinologica, 37, 75-92.
|
[29]
|
Alay, Z., Saed, G.M. and Diamond, M.P. (2006) Female Infertility and Free Radicals: Potential Role in Adhesion Adhesions and Endometriosis. Reproductive Sciences, 13, 390-398. http://dx.doi.org/10.1016/j.jsgi.2006.05.002
|
[30]
|
Gargett, C.E. and Masuda, H. (2010) Adult Stem Cells in the Endometrium. Molecular Human Reproduction, 16, 818- 834. http://dx.doi.org/10.1093/molehr/gaq061
|
[31]
|
Figueira, P.G., Abrão, M.S., Krikun, G. and Taylor, H. (2011) Stem Cells in Endometrium and Their Role in the Pathogenesis of Endometriosis. Annals of the New York Academy of Sciences, 1221, 10-17.
http://dx.doi.org/10.1111/j.1749-6632.2011.05969.x
|
[32]
|
Nisolle, M., Casanas-Roux, F., Anaf, V., Mine, J.M. and Donnez, J. (1993) Morphometric Study of the Stromal Vascularization in Peritoneal Endometriosis. Fertility and Sterility, 59, 681-684.
http://dx.doi.org/10.1016/S0015-0282(16)55823-3
|
[33]
|
McLaren, J. (2000) Vascular Endothelial Growth Factor and Endometriotic Angiogenesis. Human Reproduction Update, 6, 45-55. http://dx.doi.org/10.1093/humupd/6.1.45
|
[34]
|
Laschke, M.W. and Menger, M.D. (2007) In Vitro and in Vivo Approaches to Study Angiogenesis in the Pathophysiology and Therapy of Endometriosis. Human Reproduction Update, 13, 331-342.
http://dx.doi.org/10.1093/humupd/dmm006
|
[35]
|
Healy, D.L., Rogers, P.A.W., Hii, L. and Wingfield, M. (1998) Angiogenesis: A New Theory for Endometriosis. Human Reproduction Update, 4, 736-740. http://dx.doi.org/10.1093/humupd/4.5.736
|
[36]
|
Laschke, M.W., Elitzsch, A., Vollmar, B., Vajkoczy, P. and Menger, M.D. (2006) Combined Inhibition of Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor and Platelet-Derived Growth Factor, but Not Inhibition of VEGF Alone, Effectively Suppresses Angiogenesis and Vessel Maturation in Endometriotic Lesions. Human Reproduction, 21, 262-268. http://dx.doi.org/10.1093/humrep/dei308
|
[37]
|
Feng, D., Welker, S., Körbel, C., et al. (2012) Protein Kinase CK2 Is a Regulator of Angiogenesis in Endometriotic Lesions. Angiogenesis, 15, 243-252. http://dx.doi.org/10.1007/s10456-012-9256-2
|
[38]
|
Laschke, M.W. and Menger, M.D. (2012) Anti-Angiogenic Treatment Strategies for the Therapy of Endometriosis. Human Reproduction Update, 18, 682-702. http://dx.doi.org/10.1093/humupd/dms026
|
[39]
|
Anaf, V., Simon, P., El Nakadi, I., et al. (2002) Hyperalgesia, Nerve Infiltration and Nerve Growth Factor Expression in Deep Adenomyotic Nodules, Peritoneal and Ovarian Endometriosis. Human Reproduction, 17, 1895-1900.
http://dx.doi.org/10.1093/humrep/17.7.1895
|
[40]
|
Alvarez, P., Chen, X., Hendrich, J., et al. (2012) Ectopic Uterine Tissue as a Chronic Pain Generator. Neuroscience, 225, 269-282. http://dx.doi.org/10.1016/j.neuroscience.2012.08.033
|
[41]
|
Asante, A. and Taylor, R.N. (2011) Endometriosis: The Role of Neuroangiogenesis. Annual Review of Physiology, 73, 161-182. http://dx.doi.org/10.1146/annurev-physiol-012110-142158
|
[42]
|
Novella-Maestre, E., Herraiz, S., Vila-Vives, J.M., Carda, C., Ruiz-Sauri, A. and Pellicer, A. (2012) Effect of Antiangiogenic Treatment on Peritoneal Endometriosis-Associated Nerve Fibers. Fertility and Sterility, 98, 1209-1217.
http://dx.doi.org/10.1016/j.fertnstert.2012.07.1103
|
[43]
|
Ahn, S.H., Edwards, A.K., Singh, S.S., Young, S.L., Lessey, B.A. and Tayade, C. (2015) IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors. The Journal of Immunology, 195, 2591-2600. http://dx.doi.org/10.4049/jimmunol.1501138
|
[44]
|
Zhang, J.-J., Xu, Z.-M., Zhang, C.-M., Dai, H.-Y., Ji, X.-Q., Wang, X.-F. and Li, C. (2011) Pyrrolidine Dithiocarbamate Inhibits Nuclear Factor-κB Pathway Activation, and Regulates Adhesion, Migration, Invasion and Apoptosis of Endometriotic Stromal Cells. Molecular Human Reproduction, 17, 175-181. http://dx.doi.org/10.1093/molehr/gaq090
|
[45]
|
Zhang, H., Li, M.J., Wang, F.L., Liu, S., Li, J.J., Wen, Z.Q. and Zhao, X.B. (2010) Endometriotic Epithelial Cells Induce MMPs Expression in Endometrial Stromal Cells via an NFκB-Dependent Pathway. Gynecological Endocrinology, 26, 456-467. http://dx.doi.org/10.3109/09513590903366988
|
[46]
|
Nasu, K., Nishida, M., Ueda, T., Yuga, M., Takai, N. and Narahara, H. (2007) Application of the Nuclear Factor-κB Inhibitor BAY 11-7085 for the Treatment of Endometriosis: An in Vitro Study. American Journal of Physiology-En- docrinology and Metabolism, 293, E16-E23. http://dx.doi.org/10.1152/ajpendo.00135.2006
|
[47]
|
Kim, J.-H., Yang, Y.-I., Lee, K.-T., Park, H.-J. and Choi, J.-H. (2011) Costunolide Induces Apoptosis in Human Endometriotic Cells through Inhibition of the Prosurvival Akt and Nuclear Factor Kappa B Signaling Pathway. Biological and Pharmaceutical Bulletin, 34, 580-585. http://dx.doi.org/10.1248/bpb.34.580
|
[48]
|
Giudice, L.C. and Kao, L.C. (2004) Endometriosis. The Lancet, 364, 1789-1799.
http://dx.doi.org/10.1016/S0140-6736(04)17403-5
|
[49]
|
Nothnick, W.B. (2010) Endometriosis: In Search of Optimal Treatment. Minerva Ginecologica, 62, 17-31.
|
[50]
|
Pullen, N., Birch, C.L., Douglas, G.J., Hussain, Q., Pruimboom-Brees, I. and Walley, R.J. (2013) The Translational Challenge in the Development of New and Effective Therapies for Endometriosis: A Review of Confidence from Published Preclinical Efficacy Studies. Human Reproduction Update, 17, 791-802.
http://dx.doi.org/10.1093/humupd/dmr030
|
[51]
|
Laschke, M.W., Giebels, C., Nickels, L.M., Scheueur, C. and Menger, M.D. (2011) Endometrial Progenitor Cells Contribute to the Vascularization of Endometriotic Lesions. The American Journal of Pathology, 178, 442-450.
http://dx.doi.org/10.1016/j.ajpath.2010.11.037
|
[52]
|
Chung, H.W., Wen, Y., Choi, E.A., Li, H., Moon, H.S., Yu, H.K. and Polan, M.L. (2002) Pleiotrophin (PTN) and Midkine (MK) mRNA Expression in Eutopic and Ectopic Endometrium in Advanced Stage Endometriosis. Molecular Human Reproduction, 8, 350-355. http://dx.doi.org/10.1093/molehr/8.4.350
|
[53]
|
Donnez, J., Smoes, P., Gillerot, S., Casanas-Roux, F. and Nisolle, H. (1998) Vascular Endothelial Growth Factor (VEGF) in Endometriosis. Human Reproduction, 13, 1686-1690. http://dx.doi.org/10.1093/humrep/13.6.1686
|
[54]
|
Sharkey, A.M., Day, K., McPherson, A., Malik, S., Licence, D., Smith, S.K. and Charnock-Jones, D.S. (2000) Vascular Endothelial Growth Factor Expression in Human Endometrium Is Regulated by Hypoxia. The Journal of Clinical Endocrinology & Metabolism, 85, 402-409.
|
[55]
|
Hull, M.L., Charnock-Jones, D.S., Chan, C.L., Bruner-Tran, K.L., Osteen, K.G., Tom, B.D., Fan, T.P. and Smith, S.K. (2003) Antiangiogenic Agents Are Effective Inhibitors of Endometriosis. The Journal of Clinical Endocrinology & Metabolism, 88, 2889-2899. http://dx.doi.org/10.1210/jc.2002-021912
|
[56]
|
Nap, A.W., Griffioen, A.W., Dunselman, G.A., et al. (2004) Antiangiogenesis Therapy for Endometriosis. The Journal of Clinical Endocrinology & Metabolism, 89, 1089-1095. http://dx.doi.org/10.1210/jc.2003-031406
|
[57]
|
Nap, A.W., Dunselman, G.A.J., Griffioen, A.W., Mayo, K.H., Evers, J.L.H. and Groothuis, P.G. (2005) Angiostatic Agents Prevent the Development of Endometriosis-Like Lesions in the Chicken Chorioallantoic Membrane. Fertility and Sterility, 83, 793-795. http://dx.doi.org/10.1016/j.fertnstert.2004.06.080
|
[58]
|
Kamba, T. and McDonald, D.M. (2007) Mechanisms of Adverse Effects of Anti-VEGF Therapy for Cancer. British Journal of Cancer, 96, 1788-1795. http://dx.doi.org/10.1038/sj.bjc.6603813
|
[59]
|
Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992) Vascular Endothelial Growth Factor Induced by Hypoxia May Mediate Hypoxia-Initiated Angiogenesis. Nature, 359, 843-845. http://dx.doi.org/10.1038/359843a0
|
[60]
|
Harris, A.E. (2002) Hypoxia—A Key Regulatory Factor in Tumour Growth. Nature Reviews Cancer, 2, 38-47.
http://dx.doi.org/10.1038/nrc704
|
[61]
|
Becker, C.M., Rohwer, N., Funakoshi, T., Cramer, T., Bernhardt, W., Birsner, A., Folkman, J. and D’Amato, R.J. (2008) 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor-1α and Suppresses Growth of Lesions in a Mouse Model of Endometriosis. The American Journal of Pathology, 172, 534-544. http://dx.doi.org/10.2353/ajpath.2008.061244
|
[62]
|
Kulke, M.H., Chan, J.A., Meyerhardt, J.A., et al. (2011) A Prospective Phase II Study of 2-Methoxyestradiol Administered in Combination with Bevacizumab in Patients with Metastatic Carcinoid Tumors. Cancer Chemotherapy and Pharmacology, 68, 293-300. http://dx.doi.org/10.1007/s00280-010-1478-7
|
[63]
|
Dahut, W.L., Lakhani, N.J., Gulley, J.L., et al. (2006) Phase I Clinical Trial of Oral 2-Methoxyestradiol, an Antiangiogenic and Apoptotic Agent, in Patients with Solid Tumors. Cancer Biology & Therapy, 5, 22-27.
http://dx.doi.org/10.4161/cbt.5.1.2349
|
[64]
|
Verenich, S. and Gerk, P.M. (2010) Therapeutic Progress of 2-Methoxyestradiol and Its Drug Deposition Challenges. Molecular Pharmaceutics, 7, 2030-2039. http://dx.doi.org/10.1021/mp100190f
|
[65]
|
Mendel, D.B., Laird, A.D., Smolich, et al. (2000) Development of SU5416, a Selective Small Molecule Inhibitor of VEGF Receptor Tyrosine Kinase Activity, as an Anti-Angiogenesis Agent. Anti-Cancer Drugs Design, 15, 29-41.
|
[66]
|
Laschke, M.W., Elitzsch, A., Scheuer, C., Holstein, J.H., Vollmar, B. and Menger, M.D. (2006) Rapamycin Induces Regression of Endometriotic Lesions by Inhibiting Neovascularization and Cell Proliferation. British Journal of Pharmacology, 149, 137-144. http://dx.doi.org/10.1038/sj.bjp.0706857
|
[67]
|
Donaghay, M. and Lessey, B.A. (2007) Uterine Receptivity: Alterations Associated with Benign Gynecological Disease. Seminars in Reproductive Medicine, 25, 461-475. http://dx.doi.org/10.1055/s-2007-991044
|
[68]
|
Wei, Q., St Clair, J.B., Fu, T., Stratton, P. and Nieman, L.K. (2008) Reduced Expression of Biomarkers Associated with the Implantation Window in Women with Endometriosis. Fertility and Sterility, 91, 1686-1691.
http://dx.doi.org/10.1016/j.fertnstert.2008.02.121
|
[69]
|
Tiberi, F., Tropea, A., Apa, R., Romani, F., Lanzone, A. and Marana, R. (2010) Prokineticin 1 mRNA Expression in the Endometrium of Healthy Women and in the Eutopic Endometrium of Women with Endometriosis. Fertility and Sterility, 93, 2145-2149. http://dx.doi.org/10.1016/j.fertnstert.2009.01.105
|
[70]
|
Lu, Z., Hardt, J. and Kim, J.J. (2008) Global Analysis of Genes Regulated by HOXA10 in Decidualization Reveals a Role in Cell Proliferation. Molecular Human Reproduction, 14, 357-366. http://dx.doi.org/10.1093/molehr/gan023
|
[71]
|
Krumlauf, R (1994) Hox Genes in Vertebrate Development. Cell, 78, 191-201.
http://dx.doi.org/10.1016/0092-8674(94)90290-9
|
[72]
|
McGinnis, W. and Krumlauf, R. (1992) Homeobox Genes and Axial Patterning. Cell, 68, 283-302.
http://dx.doi.org/10.1016/0092-8674(92)90471-N
|
[73]
|
Tiberi, F., Tropea, A., Romani, F., Apa, R., Marana, R. and Lanzone, A. (2010) Prokineticin 1, Homeobox A10, and Progesterone Receptor Messenger Ribonucleic Acid Expression in Primary Cultures of Endometrial Stromal Cells Isolated from Endometrium of Healthy Women and from Eutopic Endometrium of Women with Endometriosis. Fertility and Sterility, 94, 2558-2563. http://dx.doi.org/10.1016/j.fertnstert.2010.03.006
|
[74]
|
Lee, K.-F., Lee, Y.-L., Chan, R.W.S., Cheong, A.W.Y., Ng, E.H.Y., Ho, P.-C. and Yeung, W.S.B. (2010) Up-Regula- tion of Endocrine Gland-Derived Vascular Endothelial Growth Factor but Not Vascular Endothelial Growth Factor in Human Ectopic Endometriotic Tissue. Fertility and Sterility, 93, 1052-1060.
http://dx.doi.org/10.1016/j.fertnstert.2008.12.001
|
[75]
|
Chen, Y. and Tseng, S.H. (2007) Review. Pro- and Anti-Angiogenesis Effects of Resveratrol. In Vivo, 21, 365-370.
|
[76]
|
Cao, Z.X., Fang, J., Xia, C., Shi, X.L. and Jiang, B.-H. (2004) trans-3,4,5’-Trihydroxystibene Inhibits Hypoxia-In- ducible Factor 1α and Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells. Clinical Cancer Research, 10, 5253-5263. http://dx.doi.org/10.1158/1078-0432.CCR-03-0588
|
[77]
|
Zhang, Q., Tang, X., Lu, Q.Y., Zhang, Z.F., Brown, J. and Li, A.D. (2005) Resveratrol Inhibits Hypoxia-Induced Accumulation of Hypoxia-Inducible Factor-1α and VEGF Expression in Human Tongue Squamous Cell Carcinoma and Hepatoma Cells. Molecular Cancer Therapeutics, 4, 1465-1474. http://dx.doi.org/10.1158/1535-7163.MCT-05-0198
|
[78]
|
Ganapathy, S., Chen, Q.H., Singh, K.P., Shankar, S. and Srivastava, R.K. (2010) Resveratrol Enhances Antitumor Activity of TRAIL in Prostate Cancer Xenografts through Activation of FOXO Transcription Factor. PLoS ONE, 5, e15627. http://dx.doi.org/10.1371/journal.pone.0015627
|
[79]
|
Kaneko, H., Anzai, T., Morisawa, M., et al. (2011) Resveratrol Prevents the Development of Abdominal Aortic Aneurysm through Attenuation of Inflammation, Oxidative Stress, and Neovascularization. Atherosclerosis, 217, 350-357.
http://dx.doi.org/10.1016/j.atherosclerosis.2011.03.042
|
[80]
|
Carmeliet, P. (2000) Mechanisms of Angiogenesis and Arteriogenesis. Nature Medicine, 6, 389-395.
|
[81]
|
Hu, Y., Sun, C.Y., Huang, J., Hong, L., Zhang, L. and Chu, Z.B. (2007) Antimyeloma Effects of Resveratrol through Inhibition of Angiogenesis. Chinese Medical Journal (England), 120, 1672-1677.
|
[82]
|
Bruner-Tran, K.L., Osteen, K.G., Taylor, H.S., Sokalska, A., Haines, K. and Duleba, A.J. (2011) Resveratrol Inhibits Development of Experimental Endometriosis in Vivo and Reduces Endometrial Stromal Cell Invasiveness in Vitro. Biology of Reproduction, 84, 106-112. http://dx.doi.org/10.1095/biolreprod.110.086744
|
[83]
|
Rudzitis-Auth, J., Menger, M.D. and Laschke, M.W. (2013) Resveratrol Is a Potent Inhibitor of Vascularization and Cell Proliferation in Experimental Endometriosis. Human Reproduction, 28, 1339-1347.
http://dx.doi.org/10.1093/humrep/det031
|
[84]
|
Dulak, J. and Jozkowicz, A. (2005) Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti- Cancer Therapy. Current Cancer Drug Targets, 5, 579-594. http://dx.doi.org/10.2174/156800905774932824
|
[85]
|
Oktem, M., Esinler, I., Eroglu, D., Haberal, N., Bayraktar, N. and Zeyneloglu, H.B. (2007) High-Dose Atorvastatin Causes Regression of Endometriotic Implants: A Rat Model. Human Reproduction, 22, 1474-1480.
http://dx.doi.org/10.1093/humrep/del505
|
[86]
|
Bruner-Tran, K.L., Osteen, K.G. and Duleba, A.J. (2009) Simvastatin Protects against the Development of Endometriosis in a Nude Mouse Model. The Journal of Clinical Endocrinology & Metabolism, 94, 2489-2494.
http://dx.doi.org/10.1210/jc.2008-2802
|
[87]
|
Vitagliano, A., Noventa, M., Quaranta, M. and Gizzo, S. (2015) Statins as Targeted “Magical Pills” for the Conservative Treatment of Endometriosis: May Potential Adverse Effects on Female Fertility Represent the “Dark Side of the Same Coin”? A Systematic Review of Literature. Reproductive Sciences, 23, 415-428.
http://dx.doi.org/10.1177/1933719115584446
|
[88]
|
Novella-Maestre, E., Carda, C., Noguera, I., Ruiz-Saurí, A., García-Velasco, J.A., Simón, C. and Pellicer, A. (2009) Dopamine Agonist Administration Causes a Reduction in Endometrial Implants through Modulation of Angiogenesis in Experimentally Induced Endometriosis. Human Reproduction, 24, 1025-1035.
http://dx.doi.org/10.1093/humrep/den499
|
[89]
|
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. and Garbe, E. (2007) Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation. The New England Journal of Medicine, 356, 29-38.
http://dx.doi.org/10.1056/NEJMoa062222
|
[90]
|
Delgado-Rosas, F., Gómez, R., Ferrero, H., Gaytan, F., Garcia-Velasco, J., Simón, C. and Pellicer, A. (2011) The Effects of Ergot and Non-Ergot-Derived Dopamine Agonists in an Experimental Mouse Model of Endometriosis. Reproduction, 142, 745-755. http://dx.doi.org/10.1530/REP-11-0223
|
[91]
|
Gómez, R., Abad, A., Delgado, F., Tamarit, S., Simón, C. and Pellicer, A. (2001) Effects of Hyperprolactinemia Treatment with the Dopamine Agonist Quinagolide on Endometriotic Lesions in Patients with Endometriosis-Asso- ciated Hyperprolactinemia. Fertility and Sterility, 95, 882e1-888e1.
|
[92]
|
Kochar Kaur, K. (2012) A Comparative Study of Treatment of Endometriosis with GnRH agonists vs Dopamine Agonists Caberlin, Statins. Controversies in Obstetrics and Gynaecology, Singapore.
|
[93]
|
Miyamoto, A., Taniguchi, F., Tagashira, Y., Watanabe, A., Harada, T. and Terakawa, N. (2009) TNFα Gene Silencing Reduced Lipopolysaccharide-Promoted Proliferation of Endometriotic Stromal Cells. American Journal of Reproductive Immunology, 61, 277-285. http://dx.doi.org/10.1111/j.1600-0897.2009.00691.x
|
[94]
|
Braun, D.P., Ding, J.C. and Dmowski, W.P. (2002) Peritoneal Fluid-Mediated Enhancement of Eutopic and Ectopic Endometrial Cell Proliferation Is Dependent on Tumor Necrosis Factor-α in Women with Endometriosis. Fertility and Sterility, 78, 727-732. http://dx.doi.org/10.1016/S0015-0282(02)03318-6
|
[95]
|
Yildirim, G., Attar, R., Ficicioglu, C., Karateke, A., Ozkan, F. and Yesildaglar, N. (2011) Etanercept Causes Regression of Endometriotic Implants in a Rat Model. Archives of Gynecology and Obstetrics, 283, 1297-1302.
http://dx.doi.org/10.1007/s00404-010-1543-9
|
[96]
|
Islimye, M., Kilic, S., Zulfikaroglu, E., Topcu, O., Zergeroglu, S. and Batioglu, S. (2011) Regression of Endometrial Autografts in a Rat Model of Endometriosis Treated with Etanercept. European Journal of Obstetrics & Gynecology and Reproductive Biology, 159, 184-189. http://dx.doi.org/10.1016/j.ejogrb.2011.06.029
|
[97]
|
Zulfikaroglu, E., Kilic, S., Islimye, M., Aydin, M., Zergeroglu, S. and Batioglu, S. (2011) Efficacy of Anti-Tumor Necrosis Factor Therapy on Endometriosis in an Experimental Rat Model. Archives of Gynecology and Obstetrics, 283, 799-804. http://dx.doi.org/10.1007/s00404-010-1434-0
|
[98]
|
Cayci, T., Akgul, E.O., Kurt, Y.G., Ceyhan, T.S., et al. (2011) The Levels of Nitric Oxide and Asymmetric Dimethylarginine in the Rat Endometriosis Model. Journal of Obstetrics and Gynaecology Research, 37, 1041-1047.
http://dx.doi.org/10.1111/j.1447-0756.2010.01482.x
|
[99]
|
Barrier, B.F., Bates, G.W., Leland, M.M., Leach, D.A., Robinson, R.D. and Propst, A.M. (2004) Efficacy of Anti- Tumor Necrosis Factor Therapy in the Treatment of Spontaneous Endometriosis in Baboons. Fertility and Sterility, 81, 775-779. http://dx.doi.org/10.1016/j.fertnstert.2003.09.034
|
[100]
|
Falconer, H., Mwenda, J.M., Chai, D.C., et al. (2006) Treatment with Anti-TNF Monoclonal Antibody (c5N) Reduces the Extent of Induced Endometriosis in the Baboon. Human Reproduction, 21, 1856-1862.
http://dx.doi.org/10.1093/humrep/del044
|
[101]
|
Koninckx, P.R., Craessaerts, M., Timmerman, D., Cornillie, F. and Kennedy, S. (2008) Anti-TNF-α Treatment for Deep Endometriosis-Associated Pain: A Randomized Placebo-Controlled Trial. Human Reproduction, 23, 2017-2023.
http://dx.doi.org/10.1093/humrep/den177
|
[102]
|
Lu, D.H., Song, H. and Shi, G. (2013) Anti-TNF-α Treatment for Pelvic Pain Associated with Endometriosis. Cochrane Database of Systematic Reviews, 3, Article No. CD0008088. http://dx.doi.org/10.1002/14651858.cd008088.pub3
|
[103]
|
Diamond, M.P., Carr, B., Dmowski, P., et al. (2014) Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. Reproductive Sciences, 21, 363-371.
http://dx.doi.org/10.1177/1933719113497292
|
[104]
|
Kochar Kaur, K. and Allahbadia, G.N. (2015) Medical Management of Leipmyomas-Emphasis for Different Geographical Regions. Journal of Gynecology and Neonatal Biology, 1, 1-8. http://dx.doi.org/10.15436/2380-5595.15.010
|
[105]
|
Chwalisz, K., Perez, M.C., DeManno, D., Winkel, C., Schubert, G. and Elger, W. (2005) Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis. Endocrine Reviews, 26, 423-438. http://dx.doi.org/10.1210/er.2005-0001
|
[106]
|
Wilkens, J., Chwalisz, K., Han, C., et al. (2008) Effects of the Selective Progesterone Receptor Modulator Asoprisnil on Uterine Artery Blood Flow, Ovarian Activity, and Clinical Symptoms in Patients with Uterine Leiomyomata Scheduled for Hysterectomy. The Journal of Clinical Endocrinology & Metabolism, 93, 466-471.
http://dx.doi.org/10.1210/jc.2008-1104
|
[107]
|
Kettel, L.M., Murphy, A.A., Morales, A.J., Ulmann, A., Baulieu, E.E. and Yen, S.S. (1996) Treatment of Endometriosis with the Antiprogesterone Mifepristone (RU486). Fertility and Sterility, 65, 23-28.
http://dx.doi.org/10.1016/S0015-0282(16)58022-4
|
[108]
|
Elger, W., Bartley, J., Schneider, B., Kaufmann, G., Schubert, G. and Chwalisz, K. (2000) Endocrine Pharmacological Characterization of Progesterone Antagonists and Progesterone Receptor Modulators with Respect to PR-Agonistic and Antagonistic Activity. Steroids, 65, 713-723. http://dx.doi.org/10.1016/S0039-128X(00)00178-1
|
[109]
|
Chishima, F., Hayakawa, S., Sugita, K., et al. (2002) Increased Expression of Cyclooxygenase-2 in Local Lesions of Endometriosis Patients. American Journal of Reproductive Immunology, 48, 50-56.
http://dx.doi.org/10.1034/j.1600-0897.2002.01101.x
|
[110]
|
Schaff, E.A. (2010) Mifepristone: Ten Years Later. Contraception, 81, 1-7.
http://dx.doi.org/10.1016/j.contraception.2009.08.004
|
[111]
|
Im, A. and Appleman, L.J. (2010) Mifepristone: Pharmacology and Clinical Impact in Reproductive Medicine, Endocrinology and Oncology. Expert Opinion on Pharmacotherapy, 11, 481-488.
http://dx.doi.org/10.1517/14656560903535880
|
[112]
|
Donnez, J., Tatarchuk, T.F., Bouchard, P., et al. (2012) Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery. The New England Journal of Medicine, 366, 409-420. http://dx.doi.org/10.1056/NEJMoa1103182
|
[113]
|
Donnez, J., Tomaszewski, J., Vázquez, F., et al. (2012) Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids. The New England Journal of Medicine, 366, 421-432. http://dx.doi.org/10.1056/NEJMoa1103180
|
[114]
|
Hayes, E.C. and Rock, J.A. (2002) COX-2 Inhibitors and Their Role in Gynecology. Obstetrical & Gynecological Survey, 57, 768-780. http://dx.doi.org/10.1097/00006254-200211000-00023
|
[115]
|
Matsuzaki, S., Canis, M., Darcha, C., Dallel, R., Okamura, K. and Mage, G. (2004) Cyclooxygenase-2 Selective Inhibitor Prevents Implantation of Eutopic Endometrium to Ectopic Sites in Rats. Fertility and Sterility, 82, 1609-1615.
http://dx.doi.org/10.1016/j.fertnstert.2004.07.946
|
[116]
|
Efstathiou, J.A., Sampson, D.A., Levine, Z., Rohan, R.M., Zurakowski, D., Folkman, J., D’Amato, R.J. and Rupnick, M.A. (2005) Nonsteroidal Antiinflammatory Drugs Differentially Suppress Endometriosis in a Murine Model. Fertility and Sterility, 83, 171-181. http://dx.doi.org/10.1016/j.fertnstert.2004.06.058
|
[117]
|
Olivares, C., Ricci, A., Bilotas, M., Barañao, R.I. and Meresman, G. (2011) The Inhibitory Effect of Celecoxib and Rosiglitazone on Experimental Endometriosis. Fertility and Sterility, 96, 428-433.
http://dx.doi.org/10.1016/j.fertnstert.2011.05.063
|
[118]
|
Olivares, C.N., Bilotas, M.A., Ricci, A.G., Barañao, R.I. and Meresman, G.F. (2013) Anastrozole and Celecoxib for Endometriosis Treatment, Good to Keep Them Apart? Reproduction, 145, 119-126.
http://dx.doi.org/10.1530/REP-12-0386
|
[119]
|
Cobellis, L., Razzi, S., De Simone, S., et al. (2004) The Treatment with a COX-2 Specific Inhibitor Is Effective in the Management of Pain Related to Endometriosis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 116, 100-102. http://dx.doi.org/10.1016/j.ejogrb.2004.02.007
|
[120]
|
Burnier, M. (2005) The Safety of Rofecoxib. Expert Opinion on Drug Safety, 4, 491-499.
http://dx.doi.org/10.1517/14740338.4.3.491
|
[121]
|
Lebovic, D.I., Mwenda, J.M., Chai, D.C., Mueller, M.D., Santi, A., Fisseha, S. and D’Hooghe, T. (2007) PPAR- Gamma Receptor Ligand Induces Regression of Endometrial Explants in Baboons: A Prospective, Randomized, Placebo- and Drug-Controlled Study. Fertility and Sterility, 88, 1108-1119.
http://dx.doi.org/10.1016/j.fertnstert.2006.12.072
|
[122]
|
Rubin, G.L., Zhao, Y., Kalus, A.M. and Simpson, E.R. (2000) Peroxisome Proliferator-Activated Receptor Gamma Ligands Inhibit Estrogen Biosynthesis in Human Breast Adipose Tissue: Possible Implications for Breast Cancer Therapy. Cancer Research, 60, 1604-1608.
|
[123]
|
Ohama, Y., Harada, T., Iwabe, T., Taniguchi, F., Takenaka, Y. and Terakawa, N. (2008) Peroxisome Proliferator-Ac- tivated Receptor-γ Ligand Reduced Tumor Necrosis Factor-α-Induced Interleukin-8 Production and Growth in Endometriotic Stromal Cells. Fertility and Sterility, 89, 311-317. http://dx.doi.org/10.1016/j.fertnstert.2007.03.061
|
[124]
|
Wu, Y. and Guo, S.-W. (2009) Peroxisome Proliferator-Activated Receptor-Gamma and Retinoid X Receptor Agonists Synergistically Suppress Proliferation of Immortalized Endometrial Stromal Cells. Fertility and Sterility, 91, 2142- 2147. http://dx.doi.org/10.1016/j.fertnstert.2008.04.012
|
[125]
|
Lebovic, D.I., Kir, M. and Casey, CL. (2004) Peroxisome Proliferator-Activated Receptor-Gamma Agonist Rosiglitazone Reduces the Size of Experimental Endometriosis in the rat model. Fertility and Sterility, 82, 1008-1013.
http://dx.doi.org/10.1016/j.fertnstert.2004.02.148
|
[126]
|
Aytan, H., Caliskan, A.C., Demirturk, F., Aytan, P. and Koseoglu, D.R. (2007) Peroxisome Proliferator-Activated Receptor-Gamma Agonist Rosiglitazone Reduces the Size of Experimental Endometriosis in the Rat Model. Australian and New Zealand Journal of Obstetrics and Gynaecology, 47, 321-325.
http://dx.doi.org/10.1111/j.1479-828X.2007.00744.x
|
[127]
|
Demirturk, F., Aytan, H., Caliskan, A.C., Aytan, P. and Koseoglu, D.R. (2006) Effect of Peroxisome Proliferator-Ac- tivated Receptor-γ Agonist Rosiglitazone on the Induction of Endometriosis in an Experimental Rat Model. Journal of the Society for Gynecologic Investigation, 13, 58-62. http://dx.doi.org/10.1016/j.jsgi.2005.10.002
|
[128]
|
Lebovic, D.I., Mwenda, J.M., Chai, D.C., Santi, A., Xu, X. and D’Hooghe, T. (2010) Peroxisome Proliferator-Acti- vated Receptor-γ Receptor Ligand Partially Prevents the Development of Endometrial Explants in Baboons: A Prospective, Randomized, Placebo-Controlled Study. Endocrinology, 151, 1846-1852.
http://dx.doi.org/10.1210/en.2009-1076
|
[129]
|
Onalan, G., Zeyneloglu, H.B. and Bayraktar, N. (2009) Fenofibrate Causes Regression of Endometriotic Implants: A Rat Model. Fertility and Sterility, 92, 2100-2102. http://dx.doi.org/10.1016/j.fertnstert.2009.05.065
|
[130]
|
Simasko, S.M., Braileanu, G.T., Speth, R.C., Mirando, M.A., Daubert, D. and Hu, J.B. (2002) Angiotensin II Increases Intracellular Calcium Concentration in Pig Endometrial Stromal Cells through Type 1 Angiotensin Receptors, but Does Not Stimulate Phospholipase C Activity or Prostaglandin F2α Secretion. Reproduction, Fertility and Development, 14, 199-205. http://dx.doi.org/10.1071/RD02003
|
[131]
|
Carbajo-Lozoya, J., Lutz, S., Feng, Y., Kroll, J., Hammes, H.P. and Wieland, T. (2012) Angiotensin II Modulates VEGF-Driven Angiogenesis by Opposing Effects of Type 1 and Type 2 Receptor Stimulation in the Microvascular Endothelium. Cellular Signalling, 24, 1261-1269. http://dx.doi.org/10.1016/j.cellsig.2012.02.005
|
[132]
|
MacKenzie, A. (2011) Endothelium-Derived Vasoactive Agents, AT1 Receptors and Inflammation. Pharmacology & Therapeutics, 131, 187-203. http://dx.doi.org/10.1016/j.pharmthera.2010.11.001
|
[133]
|
Nagai, N., Oike, Y., Izumi-Nagai, K., et al. (2006) Angiotensin II Type 1 Receptor-Mediated Inflammation Is Required for Choroidal Neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2252-2259.
http://dx.doi.org/10.1161/01.ATV.0000240050.15321.fe
|
[134]
|
Tamaki, Y., Nakade, Y., Yamauchi, T., et al. (2013) Angiotensin II Type 1 Receptor Antagonist Prevents Hepatic Carcinoma in Rats with Nonalcoholic Steatohepatitis. Journal of Gastroenterology, 48, 491-503.
http://dx.doi.org/10.1007/s00535-012-0651-7
|
[135]
|
Nenicu, A., Körbel, C., Gu, Y., Menger, M.D. and Laschke, M.W. (2014) Combined Blockade of Angiotensin II Type 1 Receptor and Activation of Peroxisome Proliferator-Activated Receptor-γ by Telmisartan Effectively Inhibits Vascularization and Growth of Murine Endometriosis-Like Lesions. Human Reproduction, 29, 1011-1024.
http://dx.doi.org/10.1093/humrep/deu035
|
[136]
|
Fiedler, U. and Augustin, H.G. (2006) Angiopoietins: A Link between Angiogenesis and Inflammation. Trends in Molecular Medicine, 27, 552-558. http://dx.doi.org/10.1016/j.it.2006.10.004
|
[137]
|
Ramano, M. (2010) Lipoxin and Aspirin-Triggered Lipoxins. The Scientific World Journal, 10, 1048-1064.
http://dx.doi.org/10.1100/tsw.2010.113
|
[138]
|
Baker, N., O’Meara, S.J., Scannell, M., Maderna, P. and Godson, C. (2009) Lipoxin A4: Anti-Inflammatory and Anti- Angiogenic Impact on Endothelial Cells. The Journal of Immunology, 182, 3819-3826.
http://dx.doi.org/10.4049/jimmunol.0803175
|
[139]
|
Hao, H., Liu, M., Wu, P., Cai, L., Tang, K., Yi, P., Li, Y., Chen, Y. and Ye, D. (2011) Lipoxin A4 and Its Analog Suppress Hepatocellular Carcinoma via Remodeling Tumor Microenvironment. Cancer Letters, 309, 85-94.
http://dx.doi.org/10.1016/j.canlet.2011.05.020
|
[140]
|
Xu, Z., Zhao, F., Lin, F., Chen, J. and Huang, Y. (2012) Lipoxin A4 Inhibits the Development of Endometriosis in Mice: The Role of Anti-Inflammation and Anti-Angiogenesis. American Journal of Reproductive Immunology, 67, 491-497. http://dx.doi.org/10.1111/j.1600-0897.2011.01101.x
|
[141]
|
Guba, M., von Breitenbuch, P., Steinbauer, M., et al. (2002) Rapamycin Inhibits Primary and Metastatic Tumor growTh by Antiangiogenesis: Involvement of Vascular Endothelial Growth Factor. Nature Medicine, 8, 128-135.
http://dx.doi.org/10.1038/nm0202-128
|
[142]
|
Vlahos, N.F., Gregoriou, O., Deliveliotou, A., et al. (2010) Effect of Pentoxifylline on Vascular Endothelial Growth Factor C and flk-1 Expression on Endometrial Implants in the Rat Endometriosis Model. Fertility and Sterility, 93, 1316-1323. http://dx.doi.org/10.1016/j.fertnstert.2008.10.056
|
[143]
|
Olive, D.L., Lindheim, S.R. and Pritts, E.A. (2004) New Medical Treatments for Endometriosis. Best Practice & Research: Clinical Obstetrics & Gynecology, 18, 319-328. http://dx.doi.org/10.1016/j.bpobgyn.2004.03.005
|
[144]
|
Kamencic, H. and Thiel, J.A. (2008) Pentoxifylline after Conservative Surgery for Endometriosis: A Randomized, Controlled Trial. Journal of Minimally Invasive Gynecology, 15, 62-66. http://dx.doi.org/10.1016/j.jmig.2007.07.018
|
[145]
|
Alborzi, S., Ghotbi, S., Parsanezhad, M.E., Dehbashi, S., Alborzi, S. and Alborzi, M. (2007) Pentoxifylline Therapy after Laparoscopic Surgery for Different Stages of Endometriosis: A Prospective, Double-Blind, Randomized, Placebo-Controlled Study. Journal of Minimally Invasive Gynecology, 44, 54-58.
http://dx.doi.org/10.1016/j.jmig.2006.06.024
|
[146]
|
Balasch, J., Creus, M., Fábregues, F., et al. (1997) Pentoxifylline versus Placebo in the Treatment of Infertility Associated with Minimal or Mild Endometriosis: A Pilot Randomized Clinical Trial. Human Reproduction, 12, 2046-2050.
http://dx.doi.org/10.1093/humrep/12.9.2046
|
[147]
|
Creus, M., Fábregues, F., Carmona, F., del Pino, M., Manau, D. and Balasch, J. (2008) Combined Laparoscopic Surgery and Pentoxifylline Therapy for Treatment of Endometriosis-Associated Infertility: A Preliminary Trial. Human Reproduction, 23, 1910-1916. http://dx.doi.org/10.1093/humrep/den167
|
[148]
|
Lu, D., Song, H., Li, Y., Clarke, J. and Shi, G. (2012) Pentoxifylline for Endometriosis. Cochrane Database of Systematic Reviews, 1, Article No. CD00767772. http://dx.doi.org/10.1002/14651858.CD007677.pub3
|
[149]
|
Leconte, M., Santulli, P., Chouzenoux, S., et al. (2015) Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. Reproductive Sciences, 22, 1171-1180. http://dx.doi.org/10.1177/1933719115592708
|
[150]
|
Taylor, R.N., Kane, M.A. and Sidell, N .(2015) Pathogenesis of Endometriosis: Roles of Retinoids and Inflammatory Pathways. Seminars in Reproductive Medicine, 33, 246-256. http://dx.doi.org/10.1055/s-0035-1554920
|